litlas
Log inCreate account

Wei‐Ting Hwang

Active 2001–2025

Also published as
Wei-Ting Hwang
122
Papers
23,226
Citations
74
h-index
117
i10-index

Citations

Citations per year for Wei‐Ting Hwang1991: 1 citations2001: 3 citations2002: 1 citations2003: 5 citations2004: 14 citations2005: 18 citations2006: 41 citations2007: 66 citations2008: 50 citations2009: 88 citations2010: 81 citations2011: 74 citations2012: 93 citations2013: 94 citations2014: 108 citations2015: 185 citations2016: 198 citations2017: 220 citations2018: 265 citations2019: 839 citations2020: 1,167 citations2021: 1,193 citations2022: 1,042 citations2023: 784 citations2024: 1,339 citations2025: 839 citations2026: 21 citations1992–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,712 citing papers, 33.6% of this breakdownChina: 1,269 citing papers, 11.5% of this breakdownGermany: 609 citing papers, 5.5% of this breakdownUnited Kingdom: 545 citing papers, 4.9% of this breakdownItaly: 410 citing papers, 3.7% of this breakdownCanada: 401 citing papers, 3.6% of this breakdownFrance: 353 citing papers, 3.2% of this breakdownAustralia: 320 citing papers, 2.9% of this breakdownNetherlands: 308 citing papers, 2.8% of this breakdownSpain: 282 citing papers, 2.6% of this breakdownSwitzerland: 261 citing papers, 2.4% of this breakdownJapan: 219 citing papers, 2% of this breakdown
0%33.6%Other 21.3%

Institutions

Fields

  • Medicine64.6%
  • Biochemistry, Genetics and Molecular Biology18.4%
  • Immunology and Microbiology7.3%
  • Psychology2.4%
  • Health Professions1.9%
  • Social Sciences1.8%
  • Other3.6%

Topics

  • CAR-T cell therapy research14.4%
  • Virus-based gene therapy research4.8%
  • Immune Cell Function and Interaction4.6%
  • CRISPR and Genetic Engineering3.9%
  • Cancer Immunotherapy and Biomarkers3.7%
  • Immunotherapy and Immune Responses3.6%
  • Other65%

Coauthors

All papers

Open in search
  1. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

    Authors: Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C. Boesteanu, Yan Wang, Roddy S. O’Connor, Wei‐Ting Hwang, Edward Pequignot, David E Ambrose, Changfeng Zhang, Nicholas S. Wilcox, Felipe Bedoya, Corin L. Dorfmeier, Chen Fang, Lifeng Tian, Harit Parakandi, Minnal Gupta, Regina M. Young, F. Brad Johnson, Irina Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, Megan M. Davis, Bruce L. Levine, Noelle V. Frey, Donald L. Siegel, Alexander C. Huang, E. John Wherry, Hans Bitter, Jennifer L. Brogdon, David L. Porter, Carl H. June, J. Joseph Melenhorst - Nature Medicine 2018 cited by 1,770

  2. CRISPR-engineered T cells in patients with refractory cancer

    Authors: Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis, Adam D. Cohen, Kristy Weber, Eric Lancaster, Patricia Mangan, Irina Kulikovskaya, Minnal Gupta, Fang Chen, Lifeng Tian, Vanessa Gonzalez, Jun Xu, In-Young Jung, J. Joseph Melenhorst, Gabriela Plesa, Joanne Shea, Tina Matlawski, Amanda Cervini, Avery L. Gaymon, Stephanie Desjardins, Anne Lamontagne, January Salas-McKee, Andrew D. Fesnak, Donald L. Siegel, Bruce L. Levine, Julie K. Jadlowsky, Regina M. Young, Anne Chew, Wei‐Ting Hwang, Elizabeth O. Hexner, Beatriz M. Carreno, Christopher L. Nobles, Frederic D. Bushman, Kevin R. Parker, Yanyan Qi, Ansuman T. Satpathy, Howard Y. Chang, Yangbing Zhao, Simon F. Lacey, Carl H. June - Science 2020 cited by 1,484

  3. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

    Authors: Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung, Simon F. Lacey, Andrew J. Rech, Megan M. Davis, Wei‐Ting Hwang, Priti Lal, Erica L. Carpenter, Shannon L. Maude, Gabriela Plesa, Neha Vapiwala, Anne Chew, Michael Moniak, Ronnie Sebro, Michael D. Farwell, Amy Marshall, Joan Gilmore, Lester Lledo, Karen Dengel, S. Church, Tyler Hether, Jun Xu, Mercy Gohil, Thomas H. Buckingham, Stephanie S. Yee, Vanessa Gonzalez, Irina Kulikovskaya, Fang Chen, Lifeng Tian, Kyle Tien, Whitney L. Gladney, Christopher L. Nobles, Hayley E. Raymond, Prostate Cancer Cellular Therapy Program Investigators, Diane Frazee, Mary Truran, Elizabeth Veloso, Holly McConville, Jonathan Aguedelo, Samantha Hower, Sophia Ngo, Julie K. Jadlowsky, J. Joseph Melenhorst, Aoife M. Roche, J.K. Everett, Minnal Gupta, Farzana Nazimuddin, Chelsie Bartoszek, Natalka Koterba, Rachael Reynolds, Farris Ellington, Christopher C. Kloss, Ji‐Hyun Lee, Yangbing Zhao, John Scholler, James L. Riley, Christina Bailey, Andrew J. P. White, Briana M. Hudson, Pearl Chang, Marcela V. Maus, Bruce L. Levine, Elizabeth O. Hexner, Donald L. Siegel, Frederic D. Bushman, Carl H. June, Joseph A. Fraietta, Naomi B. Haas - Nature Medicine 2022 cited by 500

  4. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

    Authors: Stephen Bagley, Meghan Logun, Joseph A. Fraietta, Xin Wang, Arati Desai, Linda J. Bagley, Ali Nabavizadeh, Danuta Jarocha, Rene Martins, Eileen Maloney, Lester Lledo, Carly Stein, Amy Marshall, Rachel Leskowitz, Julie K. Jadlowsky, Shannon Christensen, Bike Su Oner, Gabriela Plesa, Andrea Brennan, Vanessa Gonzalez, Fang Chen, Yusha Sun, Whitney L. Gladney, David M. Barrett, MacLean P. Nasrallah, Wei‐Ting Hwang, Guo‐li Ming, Hongjun Song, Donald L. Siegel, Carl H. June, Elizabeth O. Hexner, Zev A. Binder, Donald M. O’Rourke - Nature Medicine 2024 cited by 336

  5. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

    Authors: David Porter, Wei‐Ting Hwang, Noelle V. Frey, Simon F. Lacey, Pamela A. Shaw, Alison W. Loren, Adam Bagg, Katherine T. Marcucci, Angela Shen, Vanessa Gonzalez, David E Ambrose, Stephan A. Grupp, Anne Chew, Zhaohui Zheng, Michael C. Milone, Bruce L. Levine, J. Joseph Melenhorst, Carl H. June - Science Translational Medicine 2015 cited by 1,727

  6. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

    Authors: Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer, J. Joseph Melenhorst, Simon F. Lacey, Eric Lancaster, Dan T. Vogl, Brendan M. Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M. Davis, Wei‐Ting Hwang, Regina M. Young, Jennifer L. Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L. Siegel, Bruce L. Levine, Carl H. June, Michael C. Milone - Journal of Clinical Investigation 2019 cited by 790

  7. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

    Authors: Stephen Bagley, Zev A. Binder, Lamia Lamrani, Eliana Marinari, Arati Desai, MacLean P. Nasrallah, Eileen Maloney, Steven Brem, Robert A. Lustig, Goldie Kurtz, Michelle Alonso‐Basanta, Pierre‐Emmanuel Bonté, Christel Goudot, Wilfrid Richer, Eliane Piaggio, Shawn Kothari, Léa Guyonnet, Coralie L. Guérin, Joshua J. Waterfall, Suyash Mohan, Wei‐Ting Hwang, Oliver Y. Tang, Meghan Logun, Meghna Bhattacharyya, Kelly Markowitz, Devora Delman, Amy Marshall, E. John Wherry, Sebastián Amigorena, Gregory L. Beatty, Jennifer L. Brogdon, Elizabeth O. Hexner, Denis Migliorini, Cécile Alanio, Donald M. O’Rourke - Nature Cancer 2024 cited by 169

  8. Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

    Authors: Divij Mathew, Melina E. Marmarelis, Caitlin Foley, Joshua Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana Davis, Maximillian Diehn, Josephine R. Giles, Alexander C. Huang, Wei‐Ting Hwang, Nancy R. Zhang, Adam J. Schoenfeld, Erica L. Carpenter, Corey J. Langer, E. John Wherry, Andy J. Minn - Science 2024 cited by 207

  9. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

    Authors: Charu Aggarwal, Jeffrey C. Thompson, Taylor A. Black, Sharyn I. Katz, Ryan Fan, Stephanie S. Yee, Austin L. Chien, Tracey L. Evans, Joshua Bauml, Evan Alley, Christine Ciunci, Abigail T. Berman, Roger B. Cohen, David Lieberman, Krishna S. Majmundar, Samantha L. Savitch, Jennifer J.D. Morrissette, Wei‐Ting Hwang, Kojo S.J. Elenitoba‐Johnson, Corey J. Langer, Erica L. Carpenter - JAMA Oncology 2018 cited by 490

  10. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV

    Authors: Pablo Tebas, David Stein, Winson W. Tang, Ian Frank, Shelley Q. Wang, Gary Lee, S. Kaye Spratt, Richard Surosky, Martin Giedlin, Geoff Nichol, Michael C. Holmes, Philip D. Gregory, Dale Ando, Michael Kalos, Ronald G. Collman, Gwendolyn Binder-Scholl, Gabriela Plesa, Wei‐Ting Hwang, Bruce L. Levine, Carl H. June - New England Journal of Medicine 2014 cited by 1,348

  11. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

    Authors: Alfred L. Garfall, Ehren K. Dancy, Adam D. Cohen, Wei‐Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst - Blood Advances 2019 cited by 229

  12. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

    Authors: Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen Callahan, Christoph T. Ellebrecht, Amrom E. Obstfeld, Simon F. Lacey, J. Joseph Melenhorst, Farzana Nazimuddin, Wei‐Ting Hwang, Shannon L. Maude, Mariusz A. Wasik, Adam Bagg, Stephen J. Schuster, Michael D. Feldman, David L. Porter, Stephen Grupp, Carl H. June, Michael C. Milone - Blood 2016 cited by 271

  13. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer

    Authors: Lova Sun, Benjamin Aaron Bleiberg, Wei‐Ting Hwang, Melina E. Marmarelis, Corey J. Langer, Aditi P. Singh, Roger B. Cohen, Ronac Mamtani, Charu Aggarwal - JAMA Oncology 2023 cited by 148

  14. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

    Authors: Wei‐Ting Hwang, Sarah F. Adams, Emin Tahirović, Ian S. Hagemann, George Coukos - Gynecologic Oncology 2011 cited by 686

  15. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

    Authors: Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W. Loren, Jakub Svoboda, Edward A. Stadtmauer, Daniel J. Landsburg, Anthony R. Mato, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, Elizabeth Veloso, Avery L. Gaymon, Edward Pequignot, Xinhe Shan, Wei‐Ting Hwang, Carl H. June, David L. Porter - Journal of Clinical Oncology 2020 cited by 185

  16. C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

    Authors: Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie‐Ming Shih, Eric J. Brown, Wei‐Ting Hwang, Deborah K. Armstrong, Stéphanie Gaillard, Robert Giuntoli, Fiona Simpkins - Clinical Cancer Research 2023 cited by 77

  17. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

    Authors: John Scholler, Troy Brady, Gwendolyn Binder-Scholl, Wei‐Ting Hwang, Gabriela Plesa, Kristen Hege, Ashley N. Vogel, Michael Kalos, James L. Riley, Steven G. Deeks, Ronald T. Mitsuyasu, Wendy B. Bernstein, Naomi Aronson, Bruce L. Levine, Frederic D. Bushman, Carl H. June - Science Translational Medicine 2012 cited by 647

  18. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

    Authors: Saar Gill, Vanessa Vides, Noelle V. Frey, Elizabeth O. Hexner, Susan Metzger, Megan A. O’Brien, Wei‐Ting Hwang, Jennifer L. Brogdon, Megan M. Davis, Joseph A. Fraietta, Avery L. Gaymon, Whitney L. Gladney, Simon F. Lacey, Anne Lamontagne, Anthony R. Mato, Marcela V. Maus, J. Joseph Melenhorst, Edward Pequignot, Marco Ruella, Maksim Shestov, John C. Byrd, Stephen J. Schuster, Donald L. Siegel, Bruce L. Levine, Carl H. June, David L. Porter - Blood Advances 2022 cited by 126

  19. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

    Authors: Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei‐Ting Hwang, Dan T. Vogl, Adam Waxman, Simon F. Lacey, Vanessa Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer - Blood Cancer Discovery 2022 cited by 76

  20. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

    Authors: Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarrin, Diego Rodriguez, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Simon A. Smith, Emma Dean, Stéphanie Gaillard, Deborah K. Armstrong, Drew A. Torigian, Wei‐Ting Hwang, Robert Giuntoli, Fiona Simpkins - Gynecologic Oncology 2021 cited by 117

  21. Cytokine-mediated CAR T therapy resistance in AML

    Authors: Anand Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick Mellors, Han R Fisher, Saamia Farooki, Benjamin F. Frost, Michael R. Loken, Avery L. Gaymon, Diane Frazee, Walter Rogal, Noelle V. Frey, Elizabeth O. Hexner, Selina M. Luger, Alison W. Loren, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Edward A. Stadtmauer, Jennifer L. Brogdon, Joseph A. Fraietta, Wei‐Ting Hwang, Don L. Siegel, Gabriela Plesa, Richard Aplenc, David L. Porter, Carl H. June, Saar Gill - Nature Medicine 2024 cited by 81

  22. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

    Authors: Peter A. Riedell, Wei‐Ting Hwang, Loretta J. Nastoupil, Martina Pennisi, Joseph P. McGuirk, Richard T. Maziarz, Veronika Bachanová, Olalekan O. Oluwole, Jamie Brower, Oscar A. Flores, Nausheen Ahmed, Levanto Schachter, Kharmen Bharucha, Bhagirathbhai Dholaria, Stephen J. Schuster, Miguel‐Angel Perales, Michael R. Bishop, David L. Porter - Transplantation and Cellular Therapy 2022 cited by 77

  23. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

    Authors: Alfred L. Garfall, Marcela V. Maus, Wei‐Ting Hwang, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem Kerr, Adam Bagg, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer - New England Journal of Medicine 2015 cited by 638

  24. Carfilzomib-Associated Cardiovascular Adverse Events

    Authors: Adam Waxman, Suparna C. Clasen, Wei‐Ting Hwang, Alfred L. Garfall, Dan T. Vogl, Joseph R. Carver, Rupal O’Quinn, Adam D. Cohen, Edward A. Stadtmauer, Bonnie Ky, Brendan M. Weiss - JAMA Oncology 2017 cited by 276